Research Article
Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience
Table 2
Clinical characteristics of hepatocellular carcinoma (HCC) patients.
| | | Mean ± SD | (, %) |
| | Tumor size (cm) | 5.7 + 5.1 | | | | Number of tumors | | | | | Single | | 117 | (49.80%) | | Two lesions | | 33 | (14.00%) | | Multiple (≥3) | | 85 | (36.20%)
| | Child-Turcotte-Pugh score | | | | | A | | 135 | (57.40%) | | B | | 75 | (31.90%) | | C | | 25 | (10.60%) | | Portal vein thrombosis | | 36 | (15.30%) | | Vascular invasion | | 28 | (11.90%) | | Metastasis | | 31 | (13.20%) | | Noncirrhotic liver | | 44 | (18.70%) | | Liver transplant | | 21 | (8.9%) | | MELD | 11 + 5 | | | | Bilirubin, μmol/L | 41.5 ± 113 | | | | Albumin, g/L | 34 ± 7 | | | | AST, U/L | 96 ± 103 | | | | ALT, U/L | 64 ± 59 | | | | INR | 1.2 ± 0.4 | | | | AFP | 10934.2 ± 48 | | | | Platelets, ×109/L | 201 ± 135 | | | | BCLC stages | | | | | Stage 0 (very early) | | 8 | (3.4%) | | Stage A (early) | | 79 | (33.6%) | | Stage B (intermediate) | | 81 | (34.5%) | | Stage C (advanced) | | 42 | (17.9%) | | Stage D (terminal) | | 25 | (10.6%) |
|
|
SD: standard deviation; MELD: model for end-stage liver disease; AFP: alpha-fetoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; INR: international normalized ratio; BCLC: Barcelona Clinic Liver Cancer.
|
